These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 32859704)

  • 1.
    Kuo HT; Lin KS; Zhang Z; Uribe CF; Merkens H; Zhang C; Bénard F
    J Nucl Med; 2021 Apr; 62(4):521-527. PubMed ID: 32859704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancing Treatment Efficacy of
    Kuo HT; Merkens H; Zhang Z; Uribe CF; Lau J; Zhang C; Colpo N; Lin KS; Bénard F
    Mol Pharm; 2018 Nov; 15(11):5183-5191. PubMed ID: 30251544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What a difference a methylene makes: replacing Glu with Asp or Aad in the Lys-urea-Glu pharmacophore of PSMA-targeting radioligands to reduce kidney and salivary gland uptake.
    Kuo HT; Lin KS; Zhang Z; Zhang C; Merkens H; Tan R; Roxin A; Uribe CF; Bénard F
    Theranostics; 2022; 12(14):6179-6188. PubMed ID: 36168623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using
    Yusufi N; Wurzer A; Herz M; D'Alessandria C; Feuerecker B; Weber W; Wester HJ; Nekolla S; Eiber M
    J Nucl Med; 2021 Aug; 62(8):1106-1111. PubMed ID: 33443072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
    Benešová M; Umbricht CA; Schibli R; Müller C
    Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of [
    Wen X; Xu P; Zeng X; Liu J; Du C; Zeng X; Cheng X; Wang X; Liang Y; Zhao T; Yang H; Li H; Meng L; Fang J; Liu H; Zhou Z; Zhang J; Zhang X; Guo Z; Chen X
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2846-2860. PubMed ID: 37097443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
    Umbricht CA; Benešová M; Schibli R; Müller C
    Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lys-urea-Aad, Lys-urea-Cmc and Lys-urea-Cms as potential pharmacophores for the design of PSMA-targeted radioligands to reduce off-target uptake in kidneys and salivary glands.
    Kuo HT; Zhang Z; Zhang C; Merkens H; Tan R; Wong AAWL; Uribe CF; Bénard F; Lin KS
    Theranostics; 2023; 13(13):4559-4573. PubMed ID: 37649602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window.
    Kelly JM; Amor-Coarasa A; Ponnala S; Nikolopoulou A; Williams C; DiMagno SG; Babich JW
    J Nucl Med; 2019 May; 60(5):656-663. PubMed ID: 30552199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Vitro and In Vivo Characterization of an
    Lütje S; Franssen GM; Herrmann K; Boerman OC; Rijpkema M; Gotthardt M; Heskamp S
    J Nucl Med; 2019 Jul; 60(7):1017-1022. PubMed ID: 30655329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity.
    Deberle LM; Benešová M; Umbricht CA; Borgna F; Büchler M; Zhernosekov K; Schibli R; Müller C
    Theranostics; 2020; 10(4):1678-1693. PubMed ID: 32042329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single Chelator-Minibody Theranostic Agents for
    Ho KV; Tatum DS; Watkinson L; Carmack T; Jia F; Mascioni A; Maitz CA; Magda D; Anderson CJ
    J Nucl Med; 2024 Sep; 65(9):1435-1442. PubMed ID: 39142831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and Preclinical Evaluation of an Albumin-Binding PSMA Ligand for
    Umbricht CA; Benešová M; Hasler R; Schibli R; van der Meulen NP; Müller C
    Mol Pharm; 2018 Dec; 15(12):5556-5564. PubMed ID: 30376344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical Investigations to Explore the Difference between the Diastereomers [
    Borgna F; Deberle LM; Busslinger SD; Tschan VJ; Walde LM; Becker AE; Schibli R; Müller C
    Mol Pharm; 2022 Jul; 19(7):2105-2114. PubMed ID: 35544699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of novel PSMA-targeting [
    Li L; Wang J; Wang G; Wang R; Jin W; Zang J; Sui H; Jia C; Jiang Y; Hong H; Zhu L; Alexoff D; Ploessl K; Kung HF; Zhu Z
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(9):2794-2805. PubMed ID: 38658392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel [
    Wang R; Jin W; Luo Y; Hong H; Zhao R; Li L; Yan L; Qiao J; Ploessl K; Zhu L; Kung HF
    Mol Pharm; 2024 Jul; 21(7):3256-3267. PubMed ID: 38856975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors.
    Kelly J; Amor-Coarasa A; Ponnala S; Nikolopoulou A; Williams C; Schlyer D; Zhao Y; Kim D; Babich JW
    Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1841-1851. PubMed ID: 29623376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical Dosimetry, Imaging, and Targeted Radionuclide Therapy Studies of Lu-177-Labeled Albumin-Binding, PSMA-Targeted CTT1403.
    Ling X; Latoche JD; Choy CJ; Kurland BF; Laymon CM; Wu Y; Salamacha N; Shen D; Geruntho JJ; Rigatti LH; Windish HP; Langton-Webster B; Berkman CE; Anderson CJ
    Mol Imaging Biol; 2020 Apr; 22(2):274-284. PubMed ID: 31321650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical dosimetric studies of
    Meléndez-Alafort L; Ferro-Flores G; Santos-Cuevas C; Ocampo-García B; Turato S; Fracasso G; Bolzati C; Rosato A; De Nardo L
    Med Phys; 2021 Jul; 48(7):4064-4074. PubMed ID: 33966284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving Theranostic Gallium-68/Lutetium-177-Labeled PSMA Inhibitors with an Albumin Binder for Prostate Cancer.
    Lee BS; Kim MH; Chu SY; Jung WJ; Jeong HJ; Lee K; Kim HS; Kim MH; Kil HS; Han SJ; Lee YJ; Lee KC; Lim SM; Chi DY
    Mol Cancer Ther; 2021 Dec; 20(12):2410-2419. PubMed ID: 34725194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.